[PDF] Top 20 SGLT2 versus DPP4 inhibitors for type 2 diabetes.

... Most of these trials were rather short-term (12-24 weeks) so that it is difficult to conclude on the long-term efficacy of each compound. Durability of the glucose-lowering effect is a crucial issue because T2DM is an ... Voir le document complet

... with type 2 ...of SGLT2 inhibitors (rifampin, inhibitors or inducers of uridine diphosphate-glucuronosyltransferase – UGT -) may result in significant changes in the exposure of ... Voir le document complet

... des SGLT2 – insuffisance cardiaque – protection cardiovasculaire – protection ...cotransporter type 2 (SGLT2) inhibitors (SGLT2i; gliflozins) exert their glu- cose-lowering effect by ... Voir le document complet

... values for sitagliptin were ...(n=225) versus placebo (n=226) as add-on therapy to sitagliptin 100 mg with or without metformin in patients with inadequately controlled T2D [64] ...(-0.5% versus 0% ... Voir le document complet

... evidence for a disease modifying osteoarthritic effect of thiazolidinediones [34] , despite promising results from animal in vivo studies [34] ...(DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) ... Voir le document complet

... kidney SGLT2 cotRanspoRteR inhibitoR foR tReating type 2 diabetes s ummaRy : Canagliflozin is an inhibitor of sodium-glucose cotransporters type 2 (SGLT2) that are ... Voir le document complet

... with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes Some sodium-glucose cotransporter type 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor ... Voir le document complet

... therapy for most individuals. [2-4] Second-line agents are diverse and increasingly ...(DPP-4) inhibitors (gliptins), [5] sodium-glucose cotransporter type 2 (SGLT2) ... Voir le document complet

... RAAS inhibitors and SGLT2 inhibitors are the two pharmaco- logic classes that have best proven to improve both surrogate and hard clinical endpoints in patients with ...marker for renal ... Voir le document complet

... Introduction Type 2 diabetes (T2D) is a chronic progressive metabolic disease characterized by hyperglycaemia, due to insulin resistance/insufficient insulin production [ 1 ...goal, for which ... Voir le document complet

... manage type 2 diabetes after failure with ...agonists versus DPP-4 inhibitors will vary long term during the progressive decline in β-cell function that is responsible for loss ... Voir le document complet

... proposed for the management of hyperglycemia in ...(DPP-4) inhibitors versus placebo (non- inferiority without superiority : see below section ...without diabetes who had insulin resistance ... Voir le document complet

... of SGLT2 inhibitors with insulin, particularly for patients who gain considerable weight with insulin therapy and maintain high HbA 1c concentrations, appears to be ...of SGLT2 ... Voir le document complet

... population. For instance, in a cohort of diabetic patients with CKD and a mean BP < 140/80 mmHg, BP was not independently associated with CKD progression ...reported for composite CV outcomes or all- ... Voir le document complet

... DPP4 inhibitors and cardiovascular risk Numerous studies have evidenced a role for GLP-1 in the cardiovascular ...in type 2 diabetic patients ... Voir le document complet

... SGLT2 inhibitors are novel glucose-lowering agents indicated for the treatment of patients with T2D ...all SGLT2 inhibitors ...neither for myocardial infarction nor for ... Voir le document complet

... options for combination ...need for specific studies for instance in insulin-treated ...need for treatments with mechanisms of action that can be used in combination with a good safety profile ... Voir le document complet

... and diabetes in non-Hispanic whites and Mexican-Americans, but not in non-Hispanic blacks, again reflecting ethnic ...and diabetes prevalence, excluding data for non-Hispanic ... Voir le document complet

... in type 2 diabetes have been recently confirmed in SERENADE (« Study Evaluating Rimonabant Efficacy in drug-NAive DiabEtic patients »), a 6- month placebo-controlled trial in overweight/obese with ... Voir le document complet

... on 2 Jun 2020 HAL is a multi-disciplinary open access archive for the deposit and dissemination of sci- entific research documents, whether they are pub- lished or ... Voir le document complet